News|Articles|November 20, 2026

DermNexus 2026 to Explore Innovations in Inflammatory Skin Disease

NP/PA Connect
Listen
0:00 / 0:00

Key Takeaways

  • DermNexus 2026 emphasizes emerging mechanisms of action and therapeutic targets to support individualized, pathway-informed management across inflammatory skin diseases.
  • Disease-focused sessions address pediatric atopic dermatitis topical advances, immune pathway overlap in vitiligo and alopecia areata, and recognition and longitudinal support in hidradenitis suppurativa.
SHOW MORE

Preview DermNexus 2026, featuring emerging dermatology therapies, inflammatory disease management, systemic comorbidities, and APP education.

Dermatology nurse practitioners (NPs), physician assistants (PAs), and clinical experts will gather in Scottsdale, Arizona, November 20–21, for DermNexus 2026: The Inflammatory Disease and Innovations Congress for NP/PAs, a 2-day educational meeting focused on emerging therapeutic approaches, evolving clinical strategies, and comprehensive management of inflammatory skin diseases.

The congress will feature expert-led presentations, interactive discussions, and case-based learning opportunities addressing advances in atopic dermatitis (AD), psoriasis, hidradenitis suppurativa (HS), vitiligo, and alopecia areata, alongside broader considerations surrounding systemic inflammation, comorbidities, and the psychological burden of chronic skin disease.

Chaired by Lauren Miller, MPAS, PA-C, of Surgical Dermatology Group in Gadsden, Alabama, the meeting will emphasize the translation of emerging scientific evidence into practical strategies for dermatology advanced practice providers (APPs).

Emerging Mechanisms of Action and Therapeutic Targets

As the inflammatory dermatology treatment landscape continues to evolve, understanding the mechanisms underlying emerging therapies remains an important component of clinical decision-making.

The congress will open with "Alphabet Soup: Making Sense of New MOAs," followed by "Spotlight on Targets in Dermatologic Diseases." These sessions will establish a foundation for exploring the therapeutic pathways and treatment targets shaping the management of inflammatory skin conditions.

The program will provide opportunities for attendees to consider how advances in immunology may inform treatment selection, individualized care, and future therapeutic approaches across multiple disease states.

Advances in Atopic Dermatitis, Vitiligo, Alopecia Areata, and HS

Disease-specific discussions will examine clinical challenges and evolving management strategies across several chronic inflammatory conditions.

A spotlight continuing education symposium, "Pediatric Atopic Dermatitis: Role of Advanced Topical Therapies in Optimizing Management," will focus on the role of advanced topical treatments in pediatric AD care.

The session "Cross Talk: Immune Pathways in Vitiligo & Alopecia Areata" will explore the immunologic connections between these conditions, highlighting the importance of understanding disease mechanisms as targeted therapeutic options continue to evolve.

HS will also receive dedicated attention through "Hidden Disease: Recognizing, Treating & Supporting Patients with HS." The session will address an inflammatory disease associated with diagnostic challenges, recurrent lesions, and substantial effects on patient quality of life.

In addition to the accredited educational sessions, the program includes non-continuing education product theaters addressing the IL-31 neuroimmune pathway, treatment options for moderate to severe AD, and management of plaque psoriasis in aging and clinically complex patients.

Understanding the Connections Between Skin and Systemic Health

A central theme of DermNexus 2026 will be the recognition that inflammatory skin diseases frequently extend beyond their visible cutaneous manifestations.

The session "(Rheum Connection) Beyond the Skin: How Treating Inflammation Improves Comorbidities" will examine the relationship between dermatologic inflammation and associated rheumatologic conditions, emphasizing the importance of recognizing comorbidities in clinical practice.

Similarly, "(GI Connection) Red Flags in the Exam Room: Systemic Clues Not to Miss" will focus on identifying clinical findings that may suggest gastrointestinal or broader systemic involvement.

"The Derm-Allergy Connection: Where Our Patients Overlap" will further explore the intersection of dermatologic and allergic conditions, highlighting opportunities for interdisciplinary collaboration and more comprehensive patient evaluation.

Together, these sessions will underscore the importance of looking beyond individual skin symptoms when evaluating patients with chronic inflammatory diseases.

Recognizing the Psychological Burden of Chronic Skin Disease

In addition to physical symptoms and systemic complications, the meeting will address the emotional and psychological challenges associated with dermatologic conditions.

"The Psychoderm Connection: Mental Burden of Skin Disease" will examine the relationship between dermatologic disease and mental health, with attention to the ways chronic symptoms, visible skin changes, and treatment challenges can affect patient well-being.

The session will contribute to the congress's broader emphasis on whole-patient care, including the consideration of psychosocial concerns and quality-of-life outcomes alongside traditional measures of disease activity and treatment response.

Translating Clinical Education Into Everyday Practice

Beyond its traditional educational presentations, DermNexus will incorporate interactive pod sessions on both days, providing opportunities for attendees to engage in discussions and apply emerging clinical concepts to real-world practice.

The meeting's combination of disease-specific education, therapeutic innovation, and cross-specialty perspectives reflects the increasingly complex responsibilities of dermatology NPs and PAs.

As new treatment options emerge and understanding of inflammatory disease mechanisms advances, APPs play a critical role in recognizing disease manifestations, identifying comorbidities, educating patients, and supporting individualized treatment decisions.

By emphasizing both scientific developments and practical applications, DermNexus 2026 will offer attendees opportunities to strengthen their clinical knowledge and consider new approaches to managing patients with chronic inflammatory skin diseases.

Dermatology Times will provide coverage throughout the congress, including expert interviews, session recaps, and perspectives on the latest developments in inflammatory dermatology.


Related to this article

Journal Digest: November 16
Recent dermatology research explores chronic hand eczema prevalence, cancer risk in morphea, pernio, biologic optimization in HS, and melanoma risk prediction.